ReShape Lifesciences Inc (NASDAQ:RSLS) has a beta value of 1.25 and has seen 0.73 million shares traded in the recent trading session. The company, currently valued at $6.14M, closed the recent trade at $2.57 per share which meant it lost -$0.05 on the day or -1.72% during that session. The RSLS stock price is -16047.47% off its 52-week high price of $414.99 and 13.23% above the 52-week low of $2.23. If we look at the company’s 10-day average daily trading volume, we find that it stood at 8.41 million shares traded. The 3-month trading volume is 3.01 million shares.
The consensus among analysts is that ReShape Lifesciences Inc (RSLS) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
ReShape Lifesciences Inc (NASDAQ:RSLS) trade information
Sporting -1.72% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RSLS stock price touched $2.57 or saw a rise of 15.18%. Year-to-date, ReShape Lifesciences Inc shares have moved -99.09%, while the 5-day performance has seen it change -3.56%. Over the past 30 days, the shares of ReShape Lifesciences Inc (NASDAQ:RSLS) have changed -45.91%. Short interest in the company has seen 33655.0 shares shorted with days to cover at 0.1.
ReShape Lifesciences Inc (RSLS) estimates and forecasts
The company’s shares have lost -97.70% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 80.05% over the past 5 years.
RSLS Dividends
ReShape Lifesciences Inc is expected to release its next earnings report on 2025-Apr-04 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ReShape Lifesciences Inc (NASDAQ:RSLS)’s Major holders
Insiders own 10.63% of the company shares, while shares held by institutions stand at 0.73% with a share float percentage of 0.81%. Investors are also buoyed by the number of investors in a company, with ReShape Lifesciences Inc having a total of 11.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Apr 30, 2025 , the former fund manager holds about 0.03% shares in the company for having 373.0 shares of worth $962.0 while later fund manager owns 34.0 shares of worth $87.0 as of Mar 31, 2025 , which makes it owner of about 0.00% of company’s outstanding stock.
